Acute Liver Failure Induced by Anti-infectious Drugs: Causes and Management

Current Hepatology Reports

Volumn 16, Issue 4, 2017, Pages 276-285

  Devarbhavi, Harshad ^a  

^a ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

Author keywords

Acute liver failure; Antibiotics, antituberculosis drugs; Antifungals; Antimicrobials; Antiretrovirals; Coagulopathy; Drug induced liver injury; Encephalopathy; Hepatotoxicity

Indexed keywords

EID: 85044540143     PISSN: None     EISSN: 21959595     Source Type: Journal    
DOI: 10.1007/s11901-017-0367-5     Document Type: Article

References (98)

1. K.A. Wlodzimirow S. Eslami A. Abu-Hanna et al. Systematic review: acute liver failure—one disease, more than 40 definitions Aliment Pharmacol Ther 2012 35 1245 1256 1:STN:280:DC%2BC38rltl2jug%3D%3D 10.1111/j.1365-2036.2012.05097.x 22506515
2. C. Trey L. Lipworth T.C. Chalmers et al. Fulminant hepatic failure. Presumable contribution to halothane N Engl J Med 1968 279 798 801 1:STN:280:DyaF1cvgsl2mtQ%3D%3D 10.1056/NEJM196810102791504 5676223
3. J.G. O'Grady S.W. Schalm R. Williams Acute liver failure: redefining the syndromes Lancet 1993 342 273 275 10.1016/0140-6736(93)91736-6 8101303 The original classification of ALF into hyperacute, acute, and subacute liver failures
4. W.M. Lee R.H. Squires Jr S.L. Nyberg et al. Acute liver failure: summary of a workshop Hepatology 2008 47 1401 1415 10.1002/hep.22177 18318440 3381946
5. R. Kumar V. Bhatia S. Khanal et al. Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome Hepatology 2010 51 1665 1674 1:CAS:528:DC%2BC3cXntFCqurg%3D 10.1002/hep.23534 20196116
6. G. Ostapowicz R.J. Fontana F.V. Schiodt et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States Ann Intern Med 2002 137 947 954 10.7326/0003-4819-137-12-200212170-00007 12484709
7. J. Bernuau J.P. Benhamou Classifying acute liver failure Lancet 1993 342 252 253 1:STN:280:DyaK3szitlKlsA%3D%3D 10.1016/0140-6736(93)91809-Z 8101294
8. A. Escorsell A. Mas M. de la Mata Acute liver failure in Spain: analysis of 267 cases Liver Transpl 2007 13 1389 1395 10.1002/lt.21119 17370334
9. W.A. Bower M. Johns H.S. Margolis et al. Population-based surveillance for acute liver failure Am J Gastroenterol 2007 102 2459 2463 10.1111/j.1572-0241.2007.01388.x 17608778
10. A.L. Mindikoglu L.S. Magder A. Regev Outcome of liver transplantation for drug-induced acute liver failure in the United States: analysis of the United Network for Organ Sharing database Liver Transpl 2009 15 719 729 10.1002/lt.21692 19562705
11. W. Bernal A. Hyyrylainen A. Gera et al. Lessons from look-back in acute liver failure? A single centre experience of 3300 patients J Hepatol 2013 59 74 80 10.1016/j.jhep.2013.02.010 23439263
12. W. Bernal J. Wendon Acute liver failure N Engl J Med 2013 369 2525 2534 1:CAS:528:DC%2BC2cXhslOgtbw%3D 10.1056/NEJMra1208937 24369077 Review on ALF, detailing geographic differences in causes and pathophysiology underlining multisystem organ involvement in ALF
13. M. Robles-Diaz M.I. Lucena N. Kaplowitz et al. Use of Hy’s law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury Gastroenterology 2014 147 109 118 1:CAS:528:DC%2BC2cXoslCnsbg%3D 10.1053/j.gastro.2014.03.050 24704526
14. N. Chalasani H.L. Bonkovsky R. Fontana et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study Gastroenterology 2015 148 1340 1352 10.1053/j.gastro.2015.03.006 25754159 4446235 Updated study results from the DILIN group with antibiotics being the most common among which amoxicillin–augmentin ranks first Mortality higher in those with underlying NAFLD
15. Devarbhavi H, Patil M, Reddy VV, et al. Drug-induced acute liver failure in 128 patients including children: implicated drug, outcome, predictors of mortality-results from a single-center drug-inducedliver injury registry. Hepatology. 2017;66:1674A.
16. A. Reuben D.G. Koch W.M. Lee Drug-induced acute liver failure: results of a U.S. multicenter, prospective study Hepatology 2010 52 2065 2076 10.1002/hep.23937 20949552 3992250
17. M. Oketani A. Ido N. Nakayama et al. Etiology and prognosis of fulminant hepatitis and late-onset hepatic failure in Japan: summary of the annual nationwide survey between 2004 and 2009 Hepatol Res 2013 43 97 105 10.1111/j.1872-034X.2012.01105.x 23409848
18. H. Devarbhavi R. Dierkhising W.K. Kremers Antituberculosis therapy drug-induced liver injury and acute liver failure Hepatology 2010 52 2 798 9; author reply 799-800 10.1002/hep.23805 20683973 Aug
19. K.S. Shalimar D. Gunjan et al. Acute liver failure due to hepatitis E virus infection is associated with better survival than other etiologies in Indian patients Dig Dis Sci 2017 62 1058 1066 1:CAS:528:DC%2BC2sXhslShsr4%3D 10.1007/s10620-017-4461-x 28130708
20. E. Bjornsson R. Olsson Outcome and prognostic markers in severe drug-induced liver disease Hepatology 2005 42 481 489 10.1002/hep.20800 16025496
21. H. Devarbhavi R. Dierkhising W.K. Kremers et al. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality Am J Gastroenterol 2010 105 2396 2404 10.1038/ajg.2010.287 20648003
22. D.C. Rockey L.B. Seeff J. Rochon et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method Hepatology 2010 51 2117 2126 10.1002/hep.23577 20512999 3249230
23. G. Danan C. Benichou Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries J Clin Epidemiol 1993 46 1323 1330 1:STN:280:DyaK2c%2FksFOquw%3D%3D 10.1016/0895-4356(93)90101-6 8229110
24. A. Singanayagam S. Sridhar J. Dhariwal et al. A comparison between two strategies for monitoring hepatic function during antituberculous therapy Am J Respir Crit Care Med 2012 185 653 659 1:CAS:528:DC%2BC38XmtVehurg%3D 10.1164/rccm.201105-0850OC 22198973 DILI from anti-TB drugs is 17% according to predefined DILI criteria, many of whice could be considered adaptation. No deaths from DILI
25. J.J. Saukkonen D.L. Cohn R.M. Jasmer et al. An official ATS statement: hepatotoxicity of antituberculosis therapy Am J Respir Crit Care Med 2006 174 935 952 1:CAS:528:DC%2BD28Xht1SgtLnJ 10.1164/rccm.200510-1666ST 17021358 An excellent review on antituberculosis drug hepatotoxicity
26. P. Nahid S.E. Dorman N. Alipanah et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis Clin Infect Dis 2016 63 e147 e195 10.1093/cid/ciw376 27516382
27. J. Shi M. Xie J. Wang et al. Susceptibility of N-acetyltransferase 2 slow acetylators to antituberculosis drug-induced liver injury: a meta-analysis Pharmacogenomics 2015 16 2083 2097 1:CAS:528:DC%2BC2MXhvFKjtLfI 10.2217/pgs.15.144 26616266
28. H. Devarbhavi R. Singh M. Patil et al. Outcome and determinants of mortality in 269 patients with combination anti-tuberculosis drug-induced liver injury J Gastroenterol Hepatol 2013 28 161 167 1:CAS:528:DC%2BC3sXit1Kn 10.1111/j.1440-1746.2012.07279.x 23020522 Study that showed DILI from anti-TB drugs was more common in the first 2 months, but the risk of DILI persists throughout the duration of therapy
29. H. Devarbhavi W. Kremers Fulminant hepatic failure: causes, course and predictors of outcome Indian J Gastroenterol 2005 25 A154
30. A.S. deLemos M. Ghabril D.C. Rockey et al. Amoxicillin-clavulanate-induced liver injury Dig Dis Sci 2016 61 2406 2416 1:CAS:528:DC%2BC28XkvV2ltb8%3D 10.1007/s10620-016-4121-6 27003146 4945382
31. R.J. Andrade M.I. Lucena M.C. Fernandez et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period Gastroenterology 2005 129 512 521 10.1016/j.gastro.2005.05.006 16083708
32. E.S. Bjornsson O.M. Bergmann H.K. Bjornsson et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland Gastroenterology 2013 144 1419 1425 10.1053/j.gastro.2013.02.006 23419359
33. Bessone F, Hernandez N, Lucena MI, et al. The Latin American DILI registry experience: a successful ongoing collaborative strategic initiative. Int J Mol Sci 2016;17:313.
34. C. Yazici E. Mutlu H.L. Bonkovsky et al. Risk factors for severe or fatal drug-induced liver injury from amoxicillin-clavulanic acid Hepatol Res 2015 45 676 682 1:CAS:528:DC%2BC2MXps12gt7w%3D 10.1111/hepr.12410 25163514
35. M. Sistanizad G.M. Peterson Drug-induced liver injury in the Australian setting J Clin Pharm Ther 2013 38 115 120 1:CAS:528:DC%2BC3sXjslGqs7s%3D 10.1111/jcpt.12039 23350857
36. M. Robles E. Toscano J. Cotta et al. Antibiotic-induced liver toxicity: mechanisms, clinical features and causality assessment Curr Drug Saf 2010 5 212 222 1:CAS:528:DC%2BC3cXpsFSrtrk%3D 10.2174/157488610791698307 20210729
37. E. Bjornsson P. Jerlstad A. Bergqvist et al. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden Scand J Gastroenterol 2005 40 1095 1101 10.1080/00365520510023846 16165719
38. A.K. Daly P.T. Donaldson P. Bhatnagar et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin Nat Genet 2009 41 816 819 1:CAS:528:DC%2BD1MXms1alu7o%3D 10.1038/ng.379 19483685 Seminal study demonstrating odds ratio of 80 to flucloxacillin suggesting genetic determinism as a risk factor
39. J.L. Dobson P.W. Angus R. Jones et al. Flucloxacillin-induced aplastic anaemia and liver failure Transpl Int 2005 18 487 489 10.1111/j.1432-2277.2004.00014.x 15773973
40. H. Devarbhavi S. Raj T. Joseph et al. Features and treatment of dapsone-induced hepatitis, based on analysis of 44 cases and literature review Clin Gastroenterol Hepatol 2017 26 30611 30610 A large series on dapsone DILI including a summary of published cases demonstrating a majority (88–90%) presenting with immunoallergic features and instances of acute liver failure
41. F. Zaman G. Ye K.D. Abreo et al. Successful orthotopic liver transplantation after trimethoprim-sulfamethoxazole associated fulminant liver failure Clin Transpl 2003 17 461 464 10.1034/j.1399-0012.2003.00040.x
42. C.T. Ng C.K. Tan O. CC O et al. Successful extracorporeal liver dialysis for the treatment of trimethoprim-sulfamethoxazole-induced fulminant hepatic failure Singap Med J 2013 54 e113 e116 10.11622/smedj.2013067
43. S. Agrawal A. Agarwalla Dapsone hypersensitivity syndrome: a clinico-epidemiological review J Dermatol 2005 32 883 889 10.1111/j.1346-8138.2005.tb00865.x 16361748
44. M.V. Quaresma F. Bernardes Filho J. Hezel et al. Dapsone in the treatment of pemphigus vulgaris: adverse effects and its importance as a corticosteroid sparing agent An Bras Dermatol 2015 90 51 54 10.1590/abd1806-4841.20153408 26312673 4540507
45. T.K.L. Kiang J.-A. Ford E.M. Yoshida et al. Nitrofurantoin-associated lung and liver toxicity leading to liver transplantation in a middle-aged patient Can J Hosp Pharm 2011 64 262 270 22479069 3161801
46. N. Chalasani R.J. Fontana H.L. Bonkovsky et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States Gastroenterology 2008 135 1924 1934 10.1053/j.gastro.2008.09.011 18955056 3654244
47. E. Bjornsson J. Talwalkar S. Treeprasertsuk et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis Hepatology 2010 51 2040 2048 10.1002/hep.23588 20512992
48. F. Lienart M. Morissens P. Jacobs et al. Doxycycline and hepatotoxicity Acta Clin Belg 1992 47 205 208 1:STN:280:DyaK3s%2FntVOrtQ%3D%3D 10.1080/17843286.1992.11718230 1332350
49. T.J. Urban P. Nicoletti N. Chalasani et al. Minocycline hepatotoxicity: clinical characterization and identification of HLA-B *35:02 as a risk factor J Hepatol 2017 67 137 144 1:CAS:528:DC%2BC2sXls1ygurw%3D 10.1016/j.jhep.2017.03.010 28323125 5634615
50. A. Kuhn C. Weiler-Normann C. Schramm et al. Acute liver failure following minocycline treatment—a case report and review of the literature Z Gastroenterol 2012 50 771 775 1:STN:280:DC%2BC3s%2FksVWmsQ%3D%3D 10.1055/s-0031-1299443 22895906
51. J.E. Losanoff J.M. Holder-Murray E.B. Ahmed et al. Minocycline toxicity requiring liver transplant Dig Dis Sci 2007 52 3242 3244 10.1007/s10620-006-9550-1 17404879
52. F. Ekiz O. Uskudar Z. Simsek et al. Cefuroxime axetil-induced liver failure Ann Hepatol 2010 9 3 306 20720277 Jul-Sep
53. A.D. Brinker R.T. Wassel J. Lyndly et al. Telithromycin-associated hepatotoxicity: clinical spectrum and causality assessment of 42 cases Hepatology 2009 49 250 257 10.1002/hep.22620 19085949
54. K.L. Easton-Carter W. Hardikar A.L. Smith Possible roxithromycin-induced fulminant hepatic failure in a child Pharmacotherapy 2001 21 867 870 1:STN:280:DC%2BD38%2FhvFejsQ%3D%3D 10.1592/phco.21.9.867.34552 11444584
55. P. Maggi B. Solarino P. Cassano et al. Fatal fulminant hepatitis following administration of clarithromycin in a patient chronically treated with antipsycotic drugs Immunopharmacol Immunotoxicol 2013 35 191 194 1:CAS:528:DC%2BC38Xhs1Glsb7P 10.3109/08923973.2012.705293 22804484
56. M. Masia F. Gutierrez A. Jimeno et al. Fulminant hepatitis and fatal toxic epidermal necrolysis (Lyell disease) coincident with clarithromycin administration in an alcoholic patient receiving disulfiram therapy Arch Intern Med 2002 162 474 476 10.1001/archinte.162.4.474 11863483
57. A. Tietz M.H. Heim U. Eriksson et al. Fulminant liver failure associated with clarithromycin Ann Pharmacother 2003 37 57 60 10.1345/aph.1C171 12503933
58. E. Raschi E. Poluzzi A. Koci et al. Assessing liver injury associated with antimycotics: concise literature review and clues from data mining of the FAERS database World J Hepatol 2014 6 601 612 10.4254/wjh.v6.i8.601 25232453 4163743
59. V. Lo Re 3rd D.M. Carbonari J.D. Lewis et al. Oral azole antifungal medications and risk of acute liver injury, overall and by chronic liver disease status Am J Med 2016 129 283 291 1:CAS:528:DC%2BC2MXitVGhtLvP 10.1016/j.amjmed.2015.10.029 26597673
60. W.Y. Kao S. CW S Y.S. Huang et al. Risk of oral antifungal agent-induced liver injury in Taiwanese Br J Clin Pharmacol 2014 77 180 189 1:CAS:528:DC%2BC2cXksFOl 10.1111/bcp.12178 23750489
61. E. Raschi F. de Ponti Drug- and herb-induced liver injury: progress, current challenges and emerging signals of post-marketing risk World J Hepatol 2015 7 1761 1771 10.4254/wjh.v7.i13.1761 26167249 4491905
62. N.N. Pettit J. Pisano S. Weber et al. Hepatic failure in a patient receiving itraconazole for pulmonary histoplasmosis—case report and literature review Am J Ther 2016 23 0000000000000313 10.1097/MJT.0000000000000313
63. H.Y. Lou C.L. Fang S.U. Fang et al. Hepatic failure related to itraconazole use successfully treated by corticosteroids Hepat Mon 2011 11 843 846 10.5812/kowsar.1735143X.1402 22224084 3234573
64. A. Srebrnik S. Levtov R. Ben-Ami et al. Liver failure and transplantation after itraconazole treatment for toenail onychomycosis J Eur Acad Dermatol Venereol 2005 19 205 207 1:STN:280:DC%2BD2M7it1ygtg%3D%3D 10.1111/j.1468-3083.2005.00943.x 15752292
65. M. Tuccori F. Bresci B. Guidi et al. Fatal hepatitis after long-term pulse itraconazole treatment for onychomycosis Ann Pharmacother 2008 42 1112 1117 1:CAS:528:DC%2BD1cXps1Gqsbc%3D 10.1345/aph.1L051 18523232
66. Z. Perveze M.W. Johnson R.A. Rubin et al. Terbinafine-induced hepatic failure requiring liver transplantation Liver Transpl 2007 13 162 164 10.1002/lt.21034 17192859
67. M. Nunez Clinical syndromes and consequences of antiretroviral-related hepatotoxicity Hepatology 2010 52 1143 1155 1:CAS:528:DC%2BC3cXhtFyitr3N 10.1002/hep.23716 20812358
68. S.J. Clark S. Creighton B. Portmann et al. Acute liver failure associated with antiretroviral treatment for HIV: a report of six cases J Hepatol 2002 36 295 301 10.1016/S0168-8278(01)00291-4 11830344
69. M. Jones M. Nunez Liver toxicity of antiretroviral drugs Semin Liver Dis 2012 32 167 176 1:CAS:528:DC%2BC38Xht1Cht7%2FP 10.1055/s-0032-1316472 22760656
70. L. Surgers K. Lacombe Hepatoxicity of new antiretrovirals: a systematic review Clin Res Hepatol Gastroenterol 2013 37 126 133 1:CAS:528:DC%2BC3sXktlGjsLY%3D 10.1016/j.clinre.2013.02.008 23522569
71. C. Bunchorntavakul K.R. Reddy Drug hepatotoxicity: newer agents Clin Liver Dis 2017 21 115 134 10.1016/j.cld.2016.08.009 27842767
72. I. Sanne H. Mommeja-Marin J. Hinkle et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects J Infect Dis 2005 191 825 829 1:CAS:528:DC%2BD2MXivVyhu7k%3D 10.1086/428093 15717255
73. J.C. Lopez-Delgado R.M. Mendiluce T.S. Pinol et al. Urgent liver transplantation for nevirapine-induced acute liver failure: report of a case and review of the literature Ann Transplant 2012 17 122 127 1:CAS:528:DC%2BC38Xht1OnsLfE 22466918
74. J. Jao M. Sturdevant J. del Rio Martin et al. Nevirapine-induced stevens johnson-syndrome and fulminant hepatic failure requiring liver transplantation Am J Transplant 2010 10 1713 1716 1:STN:280:DC%2BC3cnotl2qug%3D%3D 10.1111/j.1600-6143.2010.03153.x 20642694
75. L. Martin-Carbonero M. Nunez J. Gonzalez-Lahoz et al. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine HIV Clin Trials 2003 4 115 120 10.1310/N4VT-3E9U-4BKN-CRPW 12671779
76. B.S. Kappelhoff F. van Leth P.A. Robinson et al. Are adverse events of nevirapine and efavirenz related to plasma concentrations? Antivir Ther 2005 10 489 498 1:CAS:528:DC%2BD2MXos1CmsLc%3D 16038474
77. A.M. Elsharkawy U. Schwab B. McCarron et al. Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser J Clin Virol 2013 58 331 333 1:CAS:528:DC%2BC3sXpt1Cksbg%3D 10.1016/j.jcv.2013.05.003 23763943
78. A. Turkova C. Ball S. Gilmour-White et al. A paediatric case of acute liver failure associated with efavirenz-based highly active antiretroviral therapy and effective use of raltegravir in combination antiretroviral treatment after liver transplantation J Antimicrob Chemother 2009 63 3 623 625 1:CAS:528:DC%2BD1MXitVSitrY%3D 10.1093/jac/dkn548 19164417 Mar
79. D.L. Fink E. Bloch Liver transplantation for acute liver failure due to efavirenz hepatotoxicity: the importance of routine monitoring Int J STD AIDS 2013 24 831 833 10.1177/0956462413483720 23970595
80. N. Abrescia M. D'Abbraccio M. Figoni et al. Fulminant hepatic failure after the start of an efavirenz-based HAART regimen in a treatment-naive female AIDS patient without hepatitis virus co-infection J Antimicrob Chemother 2002 50 5 763 765 1:CAS:528:DC%2BD38XosVSqsr0%3D 10.1093/jac/dkf204 12407142 Nov
81. S. Qayyum H. Dong D. Kovacic et al. Combination therapy efavirenz/emtricitabine/tenofovir disoproxil fumarate associated with hepatic failure Curr Drug Saf 2012 7 391 393 10.2174/157488612805076534 23373554
82. S. Soni D.R. Churchill Y. Gilleece Abacavir-induced hepatotoxicity: a report of two cases AIDS 2008 22 18 2557 2558 10.1097/QAD.0b013e32831c8af4 19005287 Nov 30
83. E. Di Filippo D. Ripamonti M. Rizzi Abacavir-induced liver toxicity in an HIV-infected patient AIDS 2014 28 4 613 10.1097/QAD.0000000000000139 24469001 Feb 20
84. C. Haas M.R. Ziccardi J. Borgman Abacavir-induced fulminant hepatic failure in a HIV/HCV co-infected patient BMJ Case Rep 2015 15 2015 212566
85. M.S. Sulkowski S.H. Mehta R.E. Chaisson et al. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir AIDS 2004 18 2277 2284 1:CAS:528:DC%2BD2cXhtVensrnE 10.1097/00002030-200411190-00008 15577540
86. C.B. Hicks P. Cahn D.A. Cooper et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug resistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials Lancet 2006 368 466 475 1:CAS:528:DC%2BD28XotVCks7k%3D 10.1016/S0140-6736(06)69154-X 16890833
87. K.M. Chan-Tack K.A. Struble D.B. Birnkrant Intracranial hemorrhage and liver-associated deaths associated with tipranavir/ritonavir: review of cases from the FDA’s Adverse Event Reporting System AIDS Patient Care STDs 2008 22 843 850 10.1089/apc.2008.0043 19025478
88. R. Temple Hy’s law: predicting serious hepatotoxicity Pharmacoepidemiol Drug Saf 2006 15 241 243 10.1002/pds.1211 16552790
89. J.G. O'Grady G.J. Alexander K.M. Hayllar et al. Early indicators of prognosis in fulminant hepatic failure Gastroenterology 1989 97 439 445 10.1016/0016-5085(89)90081-4 2490426
90. P.S. Kamath R.H. Wiesner M. Malinchoc et al. A model to predict survival in patients with end-stage liver disease Hepatology 2001 33 464 470 1:STN:280:DC%2BD3M7kvVOqug%3D%3D 10.1053/jhep.2001.22172 11172350
91. D.G. Koch H. Tillman V. Durkalski et al. Development of a model to predict transplant-free survival of patients with acute liver failure Clin Gastroenterol Hepatol 2016 14 1199 1206 10.1016/j.cgh.2016.03.046 27085756
92. W.M. Lee L.S. Hynan L. Rossaro et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure Gastroenterology 2009 137 856 864 1:CAS:528:DC%2BD1MXhtF2isrbJ 10.1053/j.gastro.2009.06.006 19524577 3189485 A randomised study showing improved survival in early coma grades in patients with non-acetaminophen ALF
93. H. Devarbhavi S. Raj V.H. Aradya et al. Drug-induced liver injury associated with stevens-Johnson syndrome/toxic epidermal necrolysis: patient characteristics, causes, and outcome in 36 cases Hepatology 2016 63 993 999 1:CAS:528:DC%2BC28XjsFejt7Y%3D 10.1002/hep.28270 26439084
94. J. Karkhanis E.C. Verna M.S. Chang et al. Steroid use in acute liver failure Hepatology 2014 59 612 621 1:CAS:528:DC%2BC2cXhslygsbY%3D 10.1002/hep.26678 23929808
95. A.J. Czaja Acute and acute severe (fulminant) autoimmune hepatitis Dig Dis Sci 2013 58 897 914 1:CAS:528:DC%2BC3sXlslShtbw%3D 10.1007/s10620-012-2445-4 23090425
96. H.C. Gonzalez S.M. Jafri S.C. Gordon Management of acute hepatotoxicity including medical agents and liver support systems Clin Liver Dis 2017 21 163 180 10.1016/j.cld.2016.08.012 27842770
97. S. Habib O.S. Shaikh Drug-induced acute liver failure Clin Liver Dis 2017 21 151 162 10.1016/j.cld.2016.08.003 27842769
98. F.S. Larsen L.E. Schmidt C. Bernsmeier et al. High-volume plasma exchange in patients with acute liver failure: an open randomised controlled trial J Hepatol 2016 64 69 78 10.1016/j.jhep.2015.08.018 26325537